Cassidy Evelyn Lounsbury BS , Christopher J. Knott-Craig MD, FACS , Angel Doño MD , Jerry Allen CCP , Umar Boston MD , Karthik Vaidyanathan Ramakrishnan MD, FRCS
{"title":"Midterm to Long-term Outcomes After Aortic Valve Replacement With Homograft in Children","authors":"Cassidy Evelyn Lounsbury BS , Christopher J. Knott-Craig MD, FACS , Angel Doño MD , Jerry Allen CCP , Umar Boston MD , Karthik Vaidyanathan Ramakrishnan MD, FRCS","doi":"10.1016/j.atssr.2025.03.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Aortic homograft root replacement is an alternative to mechanical aortic valve replacement or a Ross operation for children with aortic valve disease. This study aimed to evaluate the long-term outcomes of aortic homograft root replacement.</div></div><div><h3>Methods</h3><div>Between 2004 and 2021, 38 children underwent replacement of their aortic valves with an aortic homograft at a single institution. Electronic medical records were reviewed. Survival and reinterventions were the 2 main end points of interest.</div></div><div><h3>Results</h3><div>The median age and weight were 14 years (interquartile range [IQR], 7-17 years) and 52 kg (IQR, 26-75 kg). Six patients were syndromic (6/38 [16%]), and 4 patients had active endocarditis (4/38 [13%]). Median aortic homograft size implanted was 23 mm in diameter (IQR, 21-24 mm). There was no early mortality and 2 late deaths (5.3%); 8 homografts (21%) were replaced at follow-up with no deaths after replacement of the homograft. Of the 38 implanted homografts, 28 (74%) were functioning well at a median of 81 months after initial implantation. The actuarial reintervention-free survival was 50% at 224 months. The Kaplan-Meier estimated survival at 220 months was 90%.</div></div><div><h3>Conclusions</h3><div>Replacement of the aortic valve with an aortic homograft is a reasonable valve substitute in children, recognizing that some of these homografts will need to be replaced over time. The risk of reoperation is low, and it can be performed safely.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 3","pages":"Pages 668-671"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of thoracic surgery short reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772993125001123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Aortic homograft root replacement is an alternative to mechanical aortic valve replacement or a Ross operation for children with aortic valve disease. This study aimed to evaluate the long-term outcomes of aortic homograft root replacement.
Methods
Between 2004 and 2021, 38 children underwent replacement of their aortic valves with an aortic homograft at a single institution. Electronic medical records were reviewed. Survival and reinterventions were the 2 main end points of interest.
Results
The median age and weight were 14 years (interquartile range [IQR], 7-17 years) and 52 kg (IQR, 26-75 kg). Six patients were syndromic (6/38 [16%]), and 4 patients had active endocarditis (4/38 [13%]). Median aortic homograft size implanted was 23 mm in diameter (IQR, 21-24 mm). There was no early mortality and 2 late deaths (5.3%); 8 homografts (21%) were replaced at follow-up with no deaths after replacement of the homograft. Of the 38 implanted homografts, 28 (74%) were functioning well at a median of 81 months after initial implantation. The actuarial reintervention-free survival was 50% at 224 months. The Kaplan-Meier estimated survival at 220 months was 90%.
Conclusions
Replacement of the aortic valve with an aortic homograft is a reasonable valve substitute in children, recognizing that some of these homografts will need to be replaced over time. The risk of reoperation is low, and it can be performed safely.